Retatrutide vs. Survodutide: The Two Next-Gen Weight Loss Drugs Compared
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated March 2026
Important: We are not doctors. Everything in this article is based on published research and publicly available clinical trial data. It is not medical advice. Talk to your physician before changing any medication or health protocol.
Key Takeaways
- Both retatrutide and survodutide activate the glucagon receptor. That shared target is what separates them from first-generation GLP-1 drugs.
- The key difference: retatrutide is a triple agonist (GIP + GLP-1 + glucagon), while survodutide is a dual agonist (glucagon + GLP-1, with no GIP component).
- Different companies: retatrutide comes from Eli Lilly; survodutide is being developed by Boehringer Ingelheim.
- Phase 2 weight loss data: retatrutide showed up to 24.2% body weight loss at 48 weeks (PMID 37366315). Survodutide showed approximately 18.7% at 46 weeks according to Boehringer Ingelheim's reported Phase 2 data (based on conference presentations; peer-reviewed publication pending).
- Neither drug is FDA approved. Both are in Phase 3 development as of 2026.
- Both are being studied for metabolic-associated steatotic liver disease (MASLD/MASH), a key unmet need beyond obesity.
Why This Comparison Matters
Most comparisons in the GLP-1 space pit approved drugs against each other. This one is different.
Retatrutide and survodutide are both investigational. Both are targeting the glucagon receptor as a key differentiator from older GLP-1 drugs. For a complete overview of retatrutide specifically, see our retatrutide guide. Both are in late-stage clinical development. And both are generating serious research attention as potential successors to the current generation of obesity pharmacotherapy.
The comparison matters now because the field is moving fast. Understanding how these two compounds differ before Phase 3 data arrives helps researchers, clinicians, and informed patients track what is actually new versus what is incremental.
Mechanism: Same Target, Different Recipe
The glucagon receptor is the shared pharmacological feature. But these drugs reach it through different combinations.
Retatrutide: GIP + GLP-1 + Glucagon
Retatrutide activates all three receptors simultaneously. The GLP-1 component reduces appetite and slows gastric emptying. The GIP component amplifies insulin response and may enhance GLP-1 signaling. The glucagon component adds direct hepatic fat oxidation and increases resting energy expenditure.
This triple activation means the drug is working through three separate pathways at once.
Survodutide: Glucagon + GLP-1 (No GIP)
Survodutide takes a different approach. It is a dual agonist targeting glucagon and GLP-1 receptors only. There is no GIP component.
This is notable because the GIP receptor is largely credited with tirzepatide's efficacy advantage over semaglutide. Survodutide skips that pathway entirely and bets instead on the glucagon + GLP-1 combination being sufficient.
The rationale: glucagon receptor activation may be a more powerful metabolic driver than GIP for certain populations, particularly those with significant liver fat burden.
What Glucagon Receptor Activation Does
Both drugs share this mechanism, so it is worth understanding clearly.
Glucagon receptor activation in the liver signals the breakdown of stored fat (glycogenolysis and lipolysis). It increases hepatic glucose production, which in the context of combined GLP-1 activation, paradoxically does not raise blood glucose because insulin secretion is simultaneously enhanced. More importantly for weight loss, it drives direct fat oxidation in the liver and adipose tissue and increases basal metabolic rate.
The net effect: the body burns more fat independent of caloric restriction, not just less fat because less food is consumed.
Clinical Data: What Phase 2 Shows
Neither drug has completed Phase 3. The data below reflects Phase 2 results. Informative but not definitive.
Retatrutide Phase 2
The core Phase 2 trial (PMID 37366315) enrolled adults with obesity (BMI 30-50) without type 2 diabetes. At 48 weeks:
- 12 mg dose: Average body weight loss of 24.2%
- 4 mg dose: Approximately 8.96 kg average weight loss (PMID 36354040)
- Fat mass reduction across dose groups: -15.2%, -26.1%, and -23.2% (PMID 40609566)
- Liver fat reduction at 12 mg, 24 weeks: 86% (PMID 38858523)
The TRIUMPH-4 trial reported 26.6% placebo-adjusted weight loss. Peer review of those results is pending as of this writing.
Survodutide Phase 2
Survodutide's Phase 2 program (Boehringer Ingelheim) showed approximately 18.7% body weight loss at 46 weeks in participants with obesity, according to Boehringer Ingelheim's reported Phase 2 data. These figures are based on conference presentations; peer-reviewed publication of the full dataset is pending. The trial included multiple dose levels, and weight loss was dose-dependent.
Survodutide also showed significant reductions in liver fat in participants with MASLD/NAFLD, consistent with the glucagon receptor's known liver effects, based on conference presentations from Boehringer Ingelheim's Phase 2 program.
Boehringer Ingelheim has advanced survodutide into the Phase 3 SYNCHRONIZE program, which is evaluating it in obesity and MASH/MASLD populations.
Comparison Table
| Factor | Retatrutide | Survodutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon | Glucagon + GLP-1 |
| Manufacturer | Eli Lilly | Boehringer Ingelheim |
| Development stage | Phase 3 (TRIUMPH program) | Phase 3 (SYNCHRONIZE program) |
| Best Phase 2 weight loss | ~24.2% at 48 weeks | ~18.7% at 46 weeks (conference data) |
| Liver fat reduction | 86% at 24 wks (12 mg) | Significant; Phase 2 data reported |
| MASH/NAFLD trial | TRIUMPH-5 | SYNCHRONIZE (dedicated MASH arm) |
| FDA approval status | Not approved | Not approved |
| Dosing | Weekly injection | Weekly injection |
| Unique side effect | Dysesthesia (8.8%-20.9%) | GI-dominant profile |
Efficacy Comparison: The Honest Read
Retatrutide's Phase 2 weight loss numbers are higher. That much is clear from published data.
But there are important caveats.
First, these are Phase 2 trials, typically smaller studies designed to identify dose ranges and safety signals, not to produce the final efficacy verdict. Phase 3 results can differ meaningfully from Phase 2.
Second, the trials enrolled somewhat different populations with different exclusion criteria. Direct numerical comparison across trials is an imperfect exercise.
Third, survodutide's lack of a GIP component means it is mechanistically simpler. Some researchers argue this is actually a design advantage: fewer receptor targets mean fewer off-target effects and a cleaner safety profile to evaluate.
What we can say: retatrutide's Phase 2 data is numerically stronger for pure weight loss endpoints. Survodutide's data is still highly competitive with the best results from approved drugs like semaglutide and tirzepatide's lower doses.
Liver Disease: A Shared Focus
Both drugs are being studied for MASH (metabolic-associated steatohepatitis) and MASLD (metabolic-associated steatotic liver disease), and this may be the most important competitive battleground beyond weight loss.
MASLD affects an estimated 25% of adults globally. There are very few approved treatments. Resmetirom (Rezdiffra) received the first FDA approval specifically for MASH in 2024, but it targets only liver pathways, not the underlying obesity.
Both retatrutide and survodutide target obesity and liver disease simultaneously through the glucagon receptor pathway. If either or both receive regulatory approval for MASH, the addressable patient population expands dramatically.
Retatrutide's TRIUMPH-5 trial is dedicated specifically to MASH. Survodutide's SYNCHRONIZE program includes a dedicated MASH cohort. Both Phase 3 programs are expected to generate pivotal data over the next two to three years.
Safety Profiles
Both drugs share the standard GLP-1 side effect profile: nausea, vomiting, diarrhea, and constipation. These are most pronounced during dose escalation and tend to diminish over time.
Retatrutide-specific: Dysesthesia (abnormal skin sensations, tingling, burning) was reported in 8.8% of lower-dose participants and 20.9% of higher-dose participants based on sponsor reporting. This appears to be linked to glucagon receptor activity and is being tracked in Phase 3. Preclinical cancer signals in glucagon receptor pathway mouse models (PMID 40094000) are under evaluation. These are animal model findings only and do not establish cancer risk in humans.
Survodutide-specific: Survodutide's Phase 2 data showed a predominantly GI-focused side effect profile. The absence of GIP receptor activation may contribute to a somewhat different tolerability experience compared to retatrutide. Full safety characterization awaits Phase 3 completion.
What Comes Next
Both Phase 3 programs are underway. The competitive dynamics here are unusual: two major pharmaceutical companies are running parallel programs targeting overlapping patient populations with related but distinct mechanisms.
The obesity pharmacotherapy space is moving toward more specialized decisions. It is unlikely that a single drug "wins." More probable is a segmented market where one compound outperforms in patients with significant liver disease, another performs better in patients with cardiovascular risk, and another leads for pure weight loss endpoints.
The head-to-head data that would resolve the retatrutide vs. survodutide question definitively does not yet exist.
What the Phase 3 Programs Need to Prove
Phase 2 data establishes a signal. Phase 3 is where that signal either holds up or falls apart.
For both TRIUMPH (retatrutide) and SYNCHRONIZE (survodutide), Phase 3 trials need to answer questions that Phase 2 could not.
For TRIUMPH: The program's primary obesity trial needs to demonstrate that retatrutide's 24.2% Phase 2 weight loss result replicates in a larger, more diverse population. Phase 2 trials typically enroll hundreds of participants. Phase 3 trials enroll thousands, with broader inclusion criteria that include patients with more comorbidities and less ideal health profiles. Weight loss percentages commonly moderate from Phase 2 to Phase 3 as the population broadens. If TRIUMPH's primary endpoint shows 20-22% weight loss, that still clears tirzepatide's benchmark. If it drops below 18%, the narrative changes.
TRIUMPH also needs to answer the cardiovascular outcomes question. Semaglutide and tirzepatide both have dedicated cardiovascular outcomes trials showing mortality and event reduction in high-risk populations. That data is what earns broad prescribing across cardiology and endocrinology. TRIUMPH includes a dedicated cardiovascular trial, and those results will matter for how retatrutide is positioned regardless of the weight loss headline.
TRIUMPH-5 specifically needs to clear the FDA's MASH histology endpoints: resolution of MASH without worsening of fibrosis, or fibrosis improvement without worsening of MASH. Resmetirom cleared this bar. Retatrutide needs to do the same if it wants a MASH indication.
For SYNCHRONIZE: Boehringer Ingelheim needs to translate conference-stage Phase 2 results into peer-reviewed Phase 3 data at scale. The 18.7% weight loss figure will need to be confirmed with the full statistical package and safety profile that regulatory reviewers require. SYNCHRONIZE's dedicated MASH arm also needs to produce histology data comparable to what resmetirom demonstrated.
The head-to-head question: The data that would definitively resolve this comparison, a randomized trial enrolling patients to retatrutide versus survodutide with identical endpoints and follow-up durations, does not exist and is unlikely to be run by either company. Competitor head-to-head trials require one manufacturer to fund a study that could demonstrate its competitor's product is superior. That almost never happens. What the field will get instead is two independent Phase 3 readouts that analysts and clinicians will compare across trial populations that are similar but not identical. Definitive resolution will take years.
Frequently Asked Questions {#faq}
What is the main difference between retatrutide and survodutide?
Retatrutide activates three receptors: GIP, GLP-1, and glucagon. Survodutide activates two: glucagon and GLP-1, with no GIP component. This makes retatrutide a triple agonist and survodutide a dual agonist. Both target the glucagon receptor, which is what distinguishes them from first-generation GLP-1 drugs.
Is retatrutide more effective than survodutide?
Phase 2 data shows higher weight loss percentages for retatrutide (24.2% at 48 weeks) compared to survodutide (approximately 18.7% at 46 weeks). These are separate trials with different populations. No head-to-head comparison exists. Phase 3 results will give a clearer picture.
Who makes survodutide?
Survodutide is being developed by Boehringer Ingelheim, a German pharmaceutical company. Retatrutide is being developed by Eli Lilly.
Can I get either drug today?
No. Neither retatrutide nor survodutide is FDA approved. Both are available only through participation in clinical trials. Do not attempt to source either compound outside of a licensed clinical setting.
Why do both drugs target the glucagon receptor?
The glucagon receptor drives fat oxidation in the liver and increases resting energy expenditure. These effects go beyond what GLP-1 activation alone produces. In populations with significant liver fat (MASLD/MASH), glucagon receptor activation may be especially important.
What is the SYNCHRONIZE program?
SYNCHRONIZE is Boehringer Ingelheim's Phase 3 clinical trial program for survodutide, evaluating the drug in obesity and metabolic liver disease populations. It runs in parallel to Eli Lilly's TRIUMPH program for retatrutide.
Related Reading
- Retatrutide vs. Tirzepatide: Triple Agonist vs. Dual Agonist
- Retatrutide and Liver Health: The MASH/MASLD Data
- How GLP-1 Peptides Work: Mechanism, Dosing, and What the Research Shows
- Weight Loss and GI Disease: How Dropping Pounds Affects Your Gut and Liver
- Semaglutide vs. Liraglutide: How to Pick the Right GLP-1 for Your Situation
Medical Disclaimer
This article is produced by the Peptide Nerds editorial team for informational and educational purposes only. We are not physicians, pharmacists, or licensed healthcare providers. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendations.
Both retatrutide and survodutide are investigational compounds. Neither is FDA approved for any indication. All drugs carry risks and contraindications that are individual to the patient.
Always consult a qualified physician before starting, changing, or stopping any medication, supplement, or health protocol.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
- Rosenstock J, et al. Retatrutide Phase 1 Clinical Trial. Diabetes Care, 2023 — Early-phase retatrutide data
- Retatrutide fat mass composition outcomes. PMID 40609566
- Retatrutide liver fat reduction, Phase 2. PMID 38858523
- Preclinical glucagon receptor cancer signal research. PMID 40094000
- Meta-analysis, triple agonist outcomes. PMID 39817343
- Meta-analysis, next-gen obesity pharmacotherapy. PMID 38367045
Schema Markup
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "Organization",
"@id": "https://peptidenerds.com/#organization",
"name": "Peptide Nerds",
"url": "https://peptidenerds.com",
"logo": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/logo.png"
}
},
{
"@type": "Article",
"@id": "https://peptidenerds.com/blog/retatrutide-vs-survodutide/#article",
"headline": "Retatrutide vs. Survodutide: The Two Next-Gen Weight Loss Drugs Compared",
"description": "Both retatrutide and survodutide activate the glucagon receptor, but they take different approaches. Here's what Phase 2 data shows about each compound.",
"datePublished": "2026-03-13",
"dateModified": "2026-03-13",
"author": {
"@type": "Organization",
"name": "Peptide Nerds Editorial Team"
},
"publisher": {
"@id": "https://peptidenerds.com/#organization"
},
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://peptidenerds.com/blog/retatrutide-vs-survodutide/"
},
"image": {
"@type": "ImageObject",
"url": "https://peptidenerds.com/images/retatrutide-vs-survodutide.jpg"
},
"keywords": "retatrutide vs survodutide, next gen weight loss drugs, glucagon GLP-1 agonist, Boehringer Ingelheim survodutide, SYNCHRONIZE trial"
},
{
"@type": "FAQPage",
"@id": "https://peptidenerds.com/blog/retatrutide-vs-survodutide/#faq",
"mainEntity": [
{
"@type": "Question",
"name": "What is the main difference between retatrutide and survodutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Retatrutide activates three receptors: GIP, GLP-1, and glucagon. Survodutide activates two: glucagon and GLP-1, with no GIP component. This makes retatrutide a triple agonist and survodutide a dual agonist."
}
},
{
"@type": "Question",
"name": "Is retatrutide more effective than survodutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Phase 2 data shows higher weight loss percentages for retatrutide (24.2% at 48 weeks) compared to survodutide (approximately 18.7% at 46 weeks). These are separate trials with different populations. No head-to-head comparison exists."
}
},
{
"@type": "Question",
"name": "Who makes survodutide?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Survodutide is being developed by Boehringer Ingelheim, a German pharmaceutical company. Retatrutide is being developed by Eli Lilly."
}
},
{
"@type": "Question",
"name": "Can I get either drug today?",
"acceptedAnswer": {
"@type": "Answer",
"text": "No. Neither retatrutide nor survodutide is FDA approved. Both are available only through participation in clinical trials."
}
},
{
"@type": "Question",
"name": "Why do both drugs target the glucagon receptor?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The glucagon receptor drives fat oxidation in the liver and increases resting energy expenditure. These effects go beyond what GLP-1 activation alone produces."
}
},
{
"@type": "Question",
"name": "What is the SYNCHRONIZE program?",
"acceptedAnswer": {
"@type": "Answer",
"text": "SYNCHRONIZE is Boehringer Ingelheim's Phase 3 clinical trial program for survodutide, evaluating the drug in obesity and metabolic liver disease populations."
}
}
]
}
]
}
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.